‘Low - T3 syndrome’ among patients with acute myocardial infarction

• Authors: Edita Jankauskienė , Jolanta-Justina Vaškelytė , Eglė Rumbinaitė
• Languages of publication: EN

Abstracts

EN

Keywords

EN

Low - T3 syndrome; Triiodothyronine; Myocardial infarction; Heart remodeling

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2014
• Volume: 9
• Issue: 1
• Pages: 10-14

Dates

published

1 - 2 - 2014

online

4 - 2 - 2014

Contributors

author

Edita Jankauskienė

• Department of Cardiology at Lithuanian University of Health Sciences Hospital, Kaunas clinics, Eiveniu st. 2, Kaunas, Lithuania

author

Jolanta-Justina Vaškelytė

• Department of Cardiology at Lithuanian University of Health Sciences Hospital, Kaunas clinics, Eiveniu st. 2, Kaunas, Lithuania

author

Eglė Rumbinaitė

• Department of Cardiology at Lithuanian University of Health Sciences Hospital, Kaunas clinics, Eiveniu st. 2, Kaunas, Lithuania

References

• [1] Kalofoutis C., Mourouzis I., Galanopoulos G., Dimopoulos A., Perimenis P., Spangu D., et al., Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction, Mol Cell Biochem., 2010, 345, 161–169 http://dx.doi.org/10.1007/s11010-010-0569-4[Crossref]
• [2] Cohn J.N., Ferrari R., Sharpe N., Cardiac remodeling-concepts and clinical implications: a consensus paper from international forum on cardiac remodeling, J Am Coll Cardiol., 2000, 35, 569–582 http://dx.doi.org/10.1016/S0735-1097(99)00630-0[Crossref]
• [3] Roberts C.S., Maclean D., Maroko P., Kloner R.A., Early and late remodeling of the left ventricle after acute myocardial infarction, Am J Cardiol., 1984, 54, 3, 407–410 http://dx.doi.org/10.1016/0002-9149(84)90206-6[Crossref]
• [4] Pirolo J.S., Hutchins G.M., Moore G.W., Infarct expansion: pathologic anglysis of 204 patients with a single myocardial infarct, J Am Coll Cardiol., 1986, 7(2), 349–354 http://dx.doi.org/10.1016/S0735-1097(86)80504-6[Crossref]
• [5] Pfeffer M.A., Braunwald E., Ventricular remodeling after myocardial infarction, Experimental observations and clinical implications, Circ J., 1990, 81(4), 1161–1172 http://dx.doi.org/10.1161/01.CIR.81.4.1161[Crossref]
• [6] Carrabba N., Parodi G., Valenti R., Migliorini A., Bellandi B., Antoniucci D., Prognostic value of reverse left ventricular remodeling after primary angioplasty for STEMI, Atherosclerosis., 2012, 222, 123–128 http://dx.doi.org/10.1016/j.atherosclerosis.2012.02.028[WoS][Crossref]
• [7] Mitchell G.F., Lamas G.A., Vaughan D.E., Pfefer M.A., Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape, J Am Coll Cardiol., 1992, 19, 1136–1144 http://dx.doi.org/10.1016/0735-1097(92)90314-D[Crossref]
• [8] Rumberger J.A., Behrenbeck T., Breen J.R., Reed J.E., Gersh B.J., Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infarction in humans, J Am Coll Cardiol., 1993, 21, 673–682 http://dx.doi.org/10.1016/0735-1097(93)90100-F[Crossref]
• [9] Springeling T., Kirschbaum S.W., Rossi A., Baks T., Karamermer Y., Schulz C., et al, Late cardiac remodeling after primary percutaneous coronary intervention-five-year cardiac magnetic resonance imaging follow-up, Circ J., 2012, 77(1), 81–88 http://dx.doi.org/10.1253/circj.CJ-12-0043[Crossref]
• [10] Galiuto L., Gabrielli F.A., Lanza G.A., Porfidia A., Paraggio L., Barcheta S., et al, Influence of left ventricular hypertrophy on microvascular dysfunction and left ventricular remodelling after acute myocardial infarction,. European Journal of Echocardiography., 2010, 11, 677–682 http://dx.doi.org/10.1093/ejechocard/jeq041[Crossref]
• [11] Galli E., Pingitore A., Iervasi G., The role of thyroid in the pathophysiology of heart failure: clinical evidence, Heart Fail Rev., 2010, 155–169 [Crossref]
• [12] Coceani M., Iervasi G., Pingitore A., Carpeggiani C., L’Abbate A., Thyroid hormone and coronary artery disease: from clinical correlations to prognostic implications, Clin Cardiol., 2009, 32(7), 380–385 http://dx.doi.org/10.1002/clc.20574[WoS][Crossref]
• [13] Coceani M., Heart disease in patients with thyroid dysfunction: hyperthyroidism, hypothyroidism and beyonm, Anadolu Kardiyol Derg., 2013, 13(1), 62–6 [PubMed]
• [14] Olivares E.L, Carvalho D.P., Thyroid hormone metabolism in heart failure: iodothyronine deiodinases in focus, Curr Opin Endocrinol Diabetes Obes., 2010, 17, 414–417 http://dx.doi.org/10.1097/MED.0b013e32833d9196[Crossref]
• [15] De Groot L.J., Non-thyroidal ilness sindrome is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies, Crit Care Clin., 2006, 22, 57–86 http://dx.doi.org/10.1016/j.ccc.2005.10.001[Crossref]
• [16] Bianco A.C, Larsen P.R., Cellular and structural biology of the deiodinases, Thyroid., 2005, 15, 777–786 http://dx.doi.org/10.1089/thy.2005.15.777[Crossref]
• [17] Iervasi G., Pingitore A., Landi P., Raciti M., Ripoli A., Scarlattini M., et al., Low-T3 syndrome a strong prognostic predictor of death in patients with heart disease, Circulation., 2003, 107, 708–713 http://dx.doi.org/10.1161/01.CIR.0000048124.64204.3F[Crossref]
• [18] Gereben B., Zavacki A.M., Ribich S., Kim B.W., Huang S.A., Simonides W.S., et al, Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling, Endocr Rev., 2008, 29, 898–938 http://dx.doi.org/10.1210/er.2008-0019[WoS][Crossref]
• [19] Simonides W.S., Cardiac thyroid-hormone deiodinative pathways in ventricular hypertrophy and heart failure, In: Iervasi G, Pingitore A. (Eds.), Thyroid and heart failure from pathophysiology to clinics., Springer-Verlag Italia., 2009, 67–77 http://dx.doi.org/10.1007/978-88-470-1143-4_7[Crossref]
• [20] Olivares E.L., Marassi M.P., Fortunato R.S., Da Silva A.C., Costa-e-Sousa R.H., Araujo I.G., et al., Thyroid function disturbance and type 3 iodothyronine deiodinase induction after myocardial infarction in rats a time course stud,. Endocrinology., 2007, 148, 4786–4792 http://dx.doi.org/10.1210/en.2007-0043[WoS][Crossref]
• [21] Wassen F.W., Schiel A.E., Kuiper G.G., Kaptein E., Bakker O., Visser T.J., et al, Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure, Endocrinology., 2002, 143, 2812–2815
• [22] Pol C., Zuidwijk M., Deel E., Muller A., Visser T.J., Duncker D., et al, Left ventricular myocardial infarction in mice induces sustained cardiac deiodinase type III activity, XXVIII European Section Meeting of the International Society for Heart Research, Medimond International Proceedings, Bologna, Italy., 2008, 57–60
• [23] lymvaios I., Mourouzis I., Cokkinos D.V., Dimopoulos M.A., Toumanidis S.T., Pantos C., Thyroid hormone and recovery of cardiac function in patients with acute myocardial infarction: a strong association, European Journal of Endocrinology., 2011, 165, 1–9 http://dx.doi.org/10.1530/EJE-11-0062[Crossref]
• [24] Cini G., Carpi A., Mechanink J., Cini L., Camici M., Galleta F., et al., Thyroid hormones and the cardiovascular system: pathophysiology and interventions, Biomedicine and Pharmacotherapy., 2009, 63, 742–753 http://dx.doi.org/10.1016/j.biopha.2009.08.003[WoS][Crossref]
• [25] Pingitore A., Iervasi G., Triiodothyronine (T3) effects on cardiovascular system in patients with heart failure, Recent Patents Cardiovasc Drug Discov., 2008, 3, 19–27 http://dx.doi.org/10.2174/157489008783331625[Crossref]
• [26] Friberg L., Werner S., Eggertsen G., Ahnve S., Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina? Arch Intern Med. 2002; 162, 1388–1394 http://dx.doi.org/10.1001/archinte.162.12.1388[Crossref]
• [27] Ezekowitz J.A., Kaul P., Bakal JA., Armstrong P.W., Welsh R.C., Mcalister F.A., Declining in-hospital mortality and increasing heart failure incidente in elderly patients with first myocardial infarction, J Am Coll Cardiol., 2009, 53, 13–20 http://dx.doi.org/10.1016/j.jacc.2008.08.067[Crossref]
• [28] Gajarsa J.J., Kloner R.A., Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities, Heart Fail Rev., 2011, 16, 13–21 http://dx.doi.org/10.1007/s10741-010-9181-7[Crossref]
• [29] Pantos C., Mourouzis I., Xinaris C., Papadopoulou-Daifoti Z., Cokkinos D, Thyroid hormone and „cardiac metamorphosis”": potential therapeutic implications, Pharmacology and Therapeutics., 2008, 118, 277–294 http://dx.doi.org/10.1016/j.pharmthera.2008.02.011[Crossref]
• [30] Pantos C., Mourouzis I., Saranteas T., Clave G., Ligeret H., Noack-Fraissignes P., et al., Thyroid hormone improves postischemic recovery of function while limiting apoptosis: a new therapeutic approach to support hemodynamics in the setting of ischemia-reperfusion? Basic Research in Cardiology., 2009, 104, 69–77 http://dx.doi.org/10.1007/s00395-008-0758-4[Crossref][WoS]
• [31] Pantos C., Mourouzis I., Cokkinos DV., New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider? Heart Fail Rev., 2011, 16, 79–96 http://dx.doi.org/10.1007/s10741-010-9185-3[WoS][Crossref]
• [32] Pantos C., Mourouzis I., Xinaris C., Kokkinos A.D., Markais A., Dimopoulos A., et al., Time-dependent changes in the expression of thyroid hormone receptor α1 in the myocardium after acute myocardial infarction: posible implications in cardiac remodeling, Eur J Endocrinol., 2007, 156, 415–424 http://dx.doi.org/10.1530/EJE-06-0707
• [33] Pantos C., Mourouzis I., Cokkinos V., Thyroid hormone and ischemic myocardium, In: Iervasi G, Pingitore A. (Eds.), Thyroid and heart failure from pathophysiology to clinics, Springer-Verlag Italia., 2009, 131–13 http://dx.doi.org/10.1007/978-88-470-1143-4_13[Crossref]

Identifiers

DOI

10.2478/s11536-013-0230-1